Tin tức & Cập nhật

Abiraterone vs docetaxel in Asian mHSPC patients: What’s the difference?

23 Feb 2024 bởi

A real-world analysis of 574 Asian patients with metastatic hormone-sensitive prostate cancer (mHSPC) demonstrated a significantly longer progression-free survival (PFS) and similar overall survival (OS) with abiraterone plus androgen deprivation therapy (ADT) vs docetaxel plus ADT.

Abiraterone vs docetaxel in Asian mHSPC patients: What’s the difference?

23 Feb 2024

Stroke risk high among head and neck cancer survivors in SG

22 Feb 2024 bởi

Survivors of head and neck cancer (HNC) in Singapore have a more than twofold increased risk of stroke, regardless of age, cancer subsites, and treatment modalities, among others, according to a study.

Stroke risk high among head and neck cancer survivors in SG

22 Feb 2024

Veterans with higher traumatic brain injury predisposed to subsequent brain cancer

21 Feb 2024

Veterans of Iraq and Afghanistan who sustained moderate/severe and penetrating traumatic brain injury (TBI) are at increased risk of developing brain cancer, as shown in a study.

Veterans with higher traumatic brain injury predisposed to subsequent brain cancer

21 Feb 2024

5-year survival more likely in mBCC patients with nodal vs distant metastasis

21 Feb 2024

Among patients with metastatic basal cell carcinoma (mBCC), those with nodal disease appear to have a higher chance of remission, while individuals with distant metastasis tend to have persistent disease and subsequently die from it, a recent study reveals. However, the survival rates at 5 years surpass 50 percent even for those with stage IV disease.

5-year survival more likely in mBCC patients with nodal vs distant metastasis

21 Feb 2024

Androgen receptor activation holds promise in ER+/HER2- breast cancer

18 Feb 2024

The oral selective androgen receptor modulator enobosarm shows activity against ER-positive, HER2-negative advanced breast cancer, according to a phase II trial.

Androgen receptor activation holds promise in ER+/HER2- breast cancer

18 Feb 2024

SKYSCRAPER-08 hits mark in ESCC with dual checkpoint inhibition + doublet chemo

16 Feb 2024 bởi

In Asian patients with esophageal squamous cell carcinoma (ESCC), adding the TIGIT inhibitor tiragolumab and PD-L1 inhibitor atezolizumab to chemotherapy improved all outcomes in the phase III SKYSCRAPER-08 trial.

SKYSCRAPER-08 hits mark in ESCC with dual checkpoint inhibition + doublet chemo

16 Feb 2024

Potassium-competitive acid blockers linked to gastric cancer risk after H pylori eradication

15 Feb 2024

Exposure to potassium-competitive acid blockers (PCABs) may heighten the risk of developing gastric cancer after successful treatment for Helicobacter pylori infection, according to a study.